Received Jul 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 1 | Y015108 | — |
No symptoms reported; HCP called to report a temperature excursion for VARIVAX and PROQUAD. HCP reported that VARIVAX and PROQUAD were administered to multiple patients on multiple dates after being improperly stored. This case pertains to one patient who received imprope; This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 24-Jun-2025, the patient was vaccinated with an improper storage dose of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), (lot #Y015108, expiration date: 06-Sep-2026), dose number 1, (0.5 mL)(anatomical location and administration route were not reported); diluted in a sterile diluent (MERCK STERILE DILUENT), (lot # and expiration date were not reported), administered as prophylaxis. The reporter stated that Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) and Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) were administered to multiple patients on multiple dates after being improperly stored. However, this case pertains to one patient who received improperly stored Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) on 24-Jun-2025. No symptoms were reported. It was confirmed that the vaccine had a temperature excursion of 6.3 Fahrenheit degrees (F), during a time frame of 16 minutes.
Sterile diluent